DOCSLIB.ORG

Product List March 2019 - Page 1 of 53

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Product List March 2019 - Page 1 of 53 Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4 www.wessexfinechemicals.co.uk – 01233 659558 – [email protected] Product List March 2019 - Page 1 of 53 4-Ethyl-2,3-dioxo piperazine 59702-31-7 4-Hexylresorcinol 133-77-6 4-Hydroxymethyl-5-methyl-1,3-dioxolen-2-one 91526-18-0 4-Nitrophenyl (5-thiazolylmethyl) carbonate 144163-97-3 4-Sulfonamidophenylhydrazine Hydrochloride 17852-52-7 5-Hydroxymethyl thiazole 38585-74-9 70% Sulfathiazole Granule 72-14-0 7-APRA 120709-09-3 7-AVCA 79349-82-9 Abacavir Sulfate 188062-50-2 Abaloparatide 247062-33-5 Abametapir 1762-34-1 Abemaciclib 301-10-0 Abiraterone 154229-19-3 Abiraterone Acetate 154229-18-2 Acalabrulinib 1420477-60-6 Acamprosate Calcium 77337-73-6 Acebrophylline 179118-73-1 Acebutolol Hydrochloride 34381-68-5 Aceclidine Hydrochloride 6109-70-2 Aceclofenac 89796-99-6 Acefylline 652-37-9 Acefylline Piperazine 18428-63-2 / 18833-33-1 Acepromazine maleate 3598-37-6 Acetaminophen 103-90-2 Acetazolamide 59-66-5 Acetic Acid 64-19-7 ACF | Allyl chloroformate 2937-50-0 Aciclovir Sodium 69657-51-8 Acipimox 51037-30-0 www.wessexfinechemicals.co.uk – 01233 659558 – [email protected] Product List March 2019 - Page 2 of 53 Acitretin 55079-83-9 Aclidinium Bromide 320345-99-1 Acotiamide 185106-16-5 Acrivastine 87848-99-5 Acyclovir 59277-89-3 Adapalene 106685-40-9 Adefovir Dipivoxil 142340-99-6 Adiphenine Hydrochloride 64-95-9 Aescin 6805-41-0 Afatinib 439081-18-2 Afatinib Dimaleate 850140-73-7 Agomelatine 138112-76-2 Albendazole 54965-21-8 Albuterol (Salbutamol) Sulfate 51022.70-9 Alcaftadine 147084-10-4. Aldoxorubicin 151038-96-6 Aldoxorubicin Hydrochloride 1361563-03-2 Alectinib 1256580-46-7 Alectinib Hydrochloride 1256589-74-8 Alendronate Sodium 121268-17-5 Alfuzosin Hydrochloride 81403-68-1 Aliskiren Hemifumarate 173334-58-2 Alitretinoin 5300 03 8 Allantoin 97-59-6 Allopurinol 315-30-0 Allyl Estrenol 432-60-0 Allyl Iso-Propyl Acetyl Urea 528-92-7 Almotriptan Malate 181183-52-8 Alogliptin 850649-62-6. Alogliptin Benzoate 850649-62-2 Alosetron Hydrochloride 122852-69-1 www.wessexfinechemicals.co.uk – 01233 659558 – [email protected] Product List March 2019 - Page 3 of 53 Alprazolam 28981-97-7 Alprostadil 745-65-3 Althiazide 5588-16-9 Alverine Citrate 5560-59-8 Alvimopan 156053-89-3 Amantadine Hydrochloride 768-94-5 Ambrisentan 177036-94-1 Ambroxol Base 23828-92-4 Amifampridine 54-96-6 Amifampridine Phosphate 446254-47-3 Amikacin Sulfate 39831-55-5 Amiloride Hydrochloride 2016-88-8 Amiloride Hydrochloride Dihydrate 17440-83-4 Aminocaproic Acid 60-32-2 Aminosidine (Paromomycin Sulfate) 1263-89-4 Amiodarone 1951-25-3 Amiodarone Hydrochloride 19774-82-4 Amiodipine Besylate 111470-99-6 Amisulpride 53583-79-2 Amitriptyline Hydrochloride 549-18-8 Amlexanox 68302-57-8 Amlodipine 88150-42-9 Amlodipine Maleate 88150-47-4 Amlodipine Mesylate Monohydrate 440358-84-9 Amodiaquine Base 6398-98-7 Amorolfine 78613-38-4 Amoxapine 14028-44-5 Amphotericin B 1397-89-3 Ampicillin Sodium Sterile 69-52-3 Ampicillin Trihydrate Sterile 7177-48-2 Amtolmetin Guacil 87344-06-7 www.wessexfinechemicals.co.uk – 01233 659558 – [email protected] Product List March 2019 - Page 4 of 53 Amyl Meta Cresol 53043-14-4 Anagliptan 739366-20-2 Anagrelide Hydrochoride 68475-42-3 Anastrazole 120511-73-1 Anidulafungin 166663-25-8 Anisole (Methyl phenyl ether) 100-66-3 Apalutamide 956104-40-8 Apaziquone 114560-48-4 Apiprazole Micronised 129722-12-9 Apixaban 503612-47-3 Apremilast 608141-41-9 Aprepitant 170729-80-3 Arformoterol Tartrate 200815-49-2 Argatroban monohydrate 141396-28-3 Aripiprazole Lauroxil 1259305-29-7 Armodafinil 68693-11-8 Arteether 75887-54-6 Artemether 71963-77-4 Artesunate 88495-63-0 Asenapine 65576-45-6 Asenapine Maleate 85650-56-2 Atazanavir Sulfate 229975-97-7 Atenolol 29122-68-7 Atipamezole Hydrochloride 104054-27-5 Atomoxetine 82248-59-7 Atomoxetine Hydrochloride 83015-26-3 Atorvaquone 95233-18-4 Atorvastatin Ca-Amorphous 134523-03-8 Atorvastatin Calcium 134523-00-5 Atosiban 90779-69-4 Atosiban Acetate 914453-95-5 www.wessexfinechemicals.co.uk – 01233 659558 – [email protected] Product List March 2019 - Page 5 of 53 Atracurium Besylate 64228-81-5 Atropine Base 51-55-8 Atropine Sulfate 55-48-1 Avanafil 330784-47-9 Avatrombopag 677007-74-8 Axitinib 319460-85-0 Azathioprine 446-86-6 Azelastine 58581-89-8 Azelastine Hydrochloride 79307-93-0 Azilsartan 147403-03-0 Azilsartan Kamedoxomil 863031-24-7 Azilsartan Medoxomil 863031-21-4 Azithromycin 83905-01-5 Azithromycin Monohydrate 121470-24-4 Bacitracin 1405-87-4 Baclofen 1134-47-0 Bactracin Zinc 92528-87-5 Baloxavir 4985605-59-1 Balsalazide Disodium Dihydrate 150399-21-6 Baricitinib 1187594-09-7 Barnidipine Hydrochloride 104757-53-1 Batrixaban 330942-05-7 Bazedoxifene Acetate 198481-33-3 Beclomethasone Diproprionate 5534-09-8 Bedaquiline 843663-66-1 Bedaquiline Fumarate 845533-86-0 Belinostat 414864-00-9 Benazepril Hydrochloride 86541-74-4 Bendamustine 16506-27-7 Bendamustine Hydrochloride 3543-75-7 Bendroflumethiazide 73-48-3 www.wessexfinechemicals.co.uk – 01233 659558 – [email protected] Product List March 2019 - Page 6 of 53 Benperidol 2062-84-2 Benzarone 1477-19-6 Benzbromarone 3562-84-3 Benzhexol Hydrochloride / Trihexyphenidyl Hydrochloride 52-49-3 Benziodarone 1477-19-6 Benznidazole 22994-85-0 Benzoyl Peroxide 94-36-0 Benzphetamine Hydrochloride 5411-22-3 Benztropine mesylate 132-17-2 Benzydamine 642-72-8 Benzydamine Hydrochloride 132-69-4 Benzyl Alcohol 100-51-6 Benzyl chloroformate 501-53-1 Bepotastine 125602-71-3 Bepridil Hydrochloride 68099-86-5 Berberine Tannate 2086-83-1 Betadex Sulfobutyl Ether Sodium 7585-39-9 Betahistine DiHydrochloride 5579-84-0 Betahistine Mesylate 54856-23-4 Betaxolol Hydrochloride 63659-19-8 Bethanechol Chloride 590-63-6 Bevantolol Hydrochloride 42864-78-8 Bevaralactum Not Listed Bexarotene 153559-49-0 Bezafibrate 41859-67-0 Bicalutamide 90357-06-5 Bictegravir 1611493-60-7 Bictegravir Sodium 1807988-02-8 Bifendate 73536-69-3 Bifonazole 60628-96-8 Bilastine 202189-78-4 www.wessexfinechemicals.co.uk – 01233 659558 – [email protected] Product List March 2019 - Page 7 of 53 Bimatoprost 155206-00-1 Bimatoprost A 15520-6-00-1 Bioanserin 7440-44-0 Bisacodyl 603-50-9 Bismuth Subsalicylate 14882-18-9 Bisoprolol Fumarate 104344-23-2 Bisoprolol Hemifumarate 104344-23-2 Blonanserin 132810-10-7 BNPC | Bis-4-nitrophenyl carbonate 5070-13-3 Boceprevir 394730-60-0 Bosentan 147536-97-8 Bosentan Monohydrate 157212-55-0 Bosutinib 380843-75-4 Boswellia Serrata AKBA 67416-61-9 Bretylium tosylate 61-75-6 Brexipiprazole 7732-18-5 Brexpiperazole 913611-97-9 Brigatinib 1197953-54-0 Brij Solution 9002-92-0 Brimonidine Tartrate 70359-46-5 Brinzolamide 138890-62-7 Brivaracetam 357336-20-0 Bromazepam 1812-30-2 Bromfenac Sodium 120638-55-3 Bromfenac 91714-93-1 Bromhexine Hydrochloride 611-75-6 Bromopride 4093-35-0 Brompheniramine maleate 980-71-2 Budesonide 51333-22-3 Bufexamac 2438-72-4 Bumetanide 28395-03-01 www.wessexfinechemicals.co.uk – 01233 659558 – [email protected] Product List March 2019 - Page 8 of 53 Buparvaquone 88426-33-9 Bupivacain 38396-39-3 Bupivacaine Hydrochloride 14252-80-3 Bupropion Hydrochloride 31677-93-7 Buspirone 36505-84-7 Busulfan 55-98-1 Butamirate Citrate 18109-81-4 Butaphosphan 17316-67-5 Butenafine Hydrochloride 101827-46-7 Butoconazole Nitrate 64872-77-1 Butylamine / Erbumine 109-73-9 Cabazitaxel 183133-96-2 Cabozantinib 849217-68-1 Cadazolid 1025097-10-2 Caffeine 58-08-2 Calcium Dobesilate Monohydrate 20123-80-2 Camostat Mesylate 59721-29-8 Camylofin DiHydrochloride 5892-41-1 Canagliflozin 842133-18-0 Canagliflozin Hemihydrate 928672-86-0 Candesartan Cilexetil 139481-59-7 Cangrelor 163706-06-7 Cangrelor Tetrasodium 163706-36-3 Capacetabine 154361-50-9 Captopril 62571-86-2 Carbamazepine 298-46-4 Carbidopa 38821-49-7 Carbinoxamine Maleate 3505-38-2 Carboplatin 41575-94-4 Carboprost Tromethamine 58551-69-2 Carfilzomib 868540-17-4 www.wessexfinechemicals.co.uk – 01233 659558 – [email protected] Product List
Load more

Recommended publications
  • Full Text in Pdf Format
    DISEASES OF AQUATIC ORGANISMS Published July 30 Dis Aquat Org Oral pharmacological treatments for parasitic diseases of rainbow trout Oncorhynchus mykiss. 11: Gyrodactylus sp. J. L. Tojo*, M. T. Santamarina Department of Microbiology and Parasitology, Laboratory of Parasitology, Faculty of Pharmacy, Universidad de Santiago de Compostela, E-15706 Santiago de Compostela, Spain ABSTRACT: A total of 24 drugs were evaluated as regards their efficacy for oral treatment of gyro- dactylosis in rainbow trout Oncorhj~nchusmykiss. In preliminary trials, all drugs were supplied to infected fish at 40 g per kg of feed for 10 d. Twenty-two of the drugs tested (aminosidine, amprolium, benznidazole, b~thionol,chloroquine, diethylcarbamazine, flubendazole, levamisole, mebendazole, n~etronidazole,mclosamide, nitroxynil, oxibendazole, parbendazole, piperazine, praziquantel, roni- dazole, secnidazole, tetramisole, thiophanate, toltrazuril and trichlorfon) were ineffective Triclabenda- zole and nitroscanate completely eliminated the infection. Triclabendazole was effective only at the screening dosage (40 g per kg of feed for 10 d), while nitroscanate was effective at dosages as low as 0.6 g per kg of feed for 1 d. KEY WORDS: Gyrodactylosis . Rainbow trout Treatment. Drugs INTRODUCTION to the hooks of the opisthohaptor or to ulceration as a result of feeding by the parasite. The latter is the most The monogenean genus Gyrodactylus is widespread, serious. though some individual species have a restricted distri- Transmission takes place largely as a result of direct bution. Gyrodactyloses affect numerous freshwater contact between live fishes, though other pathways species including salmonids, cyprinids and ornamen- (contact between a live fish and a dead fish, or with tal fishes, as well as marine fishes including gadids, free-living parasites present in the substrate, or with pleuronectids and gobiids.
    [Show full text]
  • Table S1: Sensitivity, Specificity, PPV, NPV, and F1 Score of NLP Vs. ICD for Identification of Symptoms for (A) Biome Developm
    Table S1: Sensitivity, specificity, PPV, NPV, and F1 score of NLP vs. ICD for identification of symptoms for (A) BioMe development cohort; (B) BioMe validation cohort; (C) MIMIC-III; (D) 1 year of notes from patients in BioMe calculated using manual chart review. A) Fatigue Nausea and/or vomiting Anxiety Depression NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.99 (0.93- 0.59 (0.43- <0.00 0.25 (0.12- <0.00 <0.00 0.54 (0.33- Sensitivity 0.99 (0.9 – 1) 0.98 (0.88 -1) 0.3 (0.15-0.5) 0.85 (0.65-96) 0.02 1) 0.73) 1 0.42) 1 1 0.73) 0.57 (0.29- 0.9 (0.68- Specificity 0.89 (0.4-1) 0.75 (0.19-1) 0.68 0.97 (0.77-1) 0.03 0.98 (0.83-1) 0.22 0.81 (0.53-0.9) 0.96 (0.79-1) 0.06 0.82) 0.99) 0.99 (0.92- 0.86 (0.71- 0.94 (0.79- 0.79 (0.59- PPV 0.96 (0.82-1) 0.3 0.95 (0.66-1) 0.02 0.95 (0.66-1) 0.16 0.93 (0.68-1) 0.12 1) 0.95) 0.99) 0.92) 0.13 (0.03- <0.00 0.49 (0.33- <0.00 0.66 (0.48- NPV 0.89 (0.4-1) 0.007 0.94 (0.63-1) 0.34 (0.2-0.51) 0.97 (0.81-1) 0.86 (0.6-0.95) 0.04 0.35) 1 0.65) 1 0.81) <0.00 <0.00 <0.00 F1 Score 0.99 0.83 0.88 0.57 0.95 0.63 0.82 0.79 0.002 1 1 1 Itching Cramp Pain NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.98 (0.86- 0.24 (0.09- <0.00 0.09 (0.01- <0.00 0.52 (0.37- <0.00 Sensitivity 0.98 (0.85-1) 0.99 (0.93-1) 1) 0.45) 1 0.29) 1 0.66) 1 0.89 (0.72- 0.5 (0.37- Specificity 0.96 (0.8-1) 0.98 (0.86-1) 0.68 0.98 (0.88-1) 0.18 0.5 (0-1) 1 0.98) 0.66) 0.88 (0.69- PPV 0.96 (0.8-1) 0.8 (0.54-1) 0.32 0.8 (0.16-1) 0.22 0.99 (0.93-1) 0.98 (0.87-1) NA* 0.97) 0.98 (0.85- 0.57 (0.41- <0.00 0.58 (0.43- <0.00 NPV 0.98 (0.86-1) 0.5 (0-1) 0.02 (0-0.08) NA* 1) 0.72) 1 0.72) 1 <0.00 <0.00 <0.00 F1 Score 0.97 0.56 0.91 0.28 0.99 0.68 1 1 1 *Denotes 95% confidence intervals and P values that could not be calculated due to insufficient cells in 2x2 tables.
    [Show full text]
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No
    WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 307 ,409 B2 Chase et al. (45 ) Date of Patent: Jun . 4 , 2019 ( 54 ) MUSCARINIC COMBINATIONS AND THEIR (52 ) U . S . CI. USE FOR COMBATING CPC . .. .. A61K 31/ 4439 (2013 . 01 ) ; A61K 9 /0056 HYPOCHOLINERGIC DISORDERS OF THE (2013 . 01 ) ; A61K 9 / 7023 ( 2013 . 01 ) ; A61K CENTRAL NERVOUS SYSTEM 31 / 166 ( 2013 . 01 ) ; A61K 31 / 216 ( 2013 . 01 ) ; A61K 31 /4178 ( 2013 .01 ) ; A61K 31/ 439 (71 ) Applicant: Chase Pharmaceuticals Corporation , ( 2013 .01 ) ; A61K 31 /44 (2013 . 01 ) ; A61K Washington , DC (US ) 31/ 454 (2013 .01 ) ; A61K 31/ 4725 ( 2013 .01 ) ; A61K 31 /517 (2013 .01 ) ; A61K 45 / 06 ( 72 ) Inventors : Thomas N . Chase , Washington , DC (2013 . 01 ) (US ) ; Kathleen E . Clarence -Smith , ( 58 ) Field of Classification Search Washington , DC (US ) CPC .. A61K 31/ 167 ; A61K 31/ 216 ; A61K 31/ 439 ; A61K 31 /454 ; A61K 31 /4439 ; A61K (73 ) Assignee : Chase Pharmaceuticals Corporation , 31 /4175 ; A61K 31 /4725 Washington , DC (US ) See application file for complete search history. ( * ) Notice : Subject to any disclaimer, the term of this (56 ) References Cited patent is extended or adjusted under 35 U . S . C . 154 (b ) by 0 days . U . S . PATENT DOCUMENTS 5 ,534 ,520 A 7 / 1996 Fisher et al. ( 21) Appl . No. : 15 /260 , 996 2008 /0306103 Al 12 /2008 Fisher et al. 2011/ 0021503 A1* 1/ 2011 Chase . .. A61K 31/ 27 ( 22 ) Filed : Sep . 9 , 2016 514 / 215 2011/ 0071135 A1 * 3 / 2011 Chase . .. .. .. A61K 31/ 166 (65 ) Prior Publication Data 514 / 215 2011 /0245294 Al 10 / 2011 Paborji et al.
    [Show full text]
  • Second and Third Generation Oral Fluoroquinolones
    Therapeutic Class Overview Second and Third Generation Oral Fluoroquinolones Therapeutic Class • Overview/Summary: The second and third generation quinolones are approved to treat a variety of infections, including dermatologic, gastrointestinal, genitourinary, respiratory, as well as several miscellaneous infections.1-10 They are broad-spectrum agents that directly inhibit bacterial deoxyribonucleic acid (DNA) synthesis by blocking the actions of DNA gyrase and topoisomerase IV, which leads to bacterial cell death.11,12 The quinolones are most active against gram-negative bacilli and gram-negative cocci.12 Ciprofloxacin has the most potent activity against gram-negative bacteria. Norfloxacin, ciprofloxacin and ofloxacin have limited activity against streptococci and many anaerobes while levofloxacin and moxifloxacin have greater potency against gram-positive cocci, and moxifloxacin has enhanced activity against anaerobic bacteria.11-12 Gemifloxacin, levofloxacin and moxifloxacin are considered respiratory fluoroquinolones. They possess enhanced activity against Streptococcus pneumoniae while maintaining efficacy against Haemophilus influenzae, Moraxella catarrhalis and atypical pathogens. Resistance to the quinolones is increasing and cross-resistance among the various agents has been documented. Two mechanisms of bacterial resistance have been identified. These include mutations in chromosomal genes (DNA gyrase and/or topoisomerase IV) and altered drug permeability across the bacterial cell membranes.11-12 Clinical Guidelines support
    [Show full text]
  • Impact of Itopride and Domperidone on Sensitivity of Gastric Distention and Gastric Accommodation in Healthy Volunteers
    Impact of Itopride and Domperidone on sensitivity of gastric distention and gastric accommodation in healthy volunteers. Karen Van den Houte, Florencia Carbone, Ans Pauwels, Rita Vos, Tim Vanuytsel, Jan Tack Translational Research Center for Gastrointestinal Disorders, KULeuven, Belgium BACKGROUND & AIM RESULTS Functional dyspepsia (FD), defined as upper abdominal symptoms affecting Conduct of the study Gastric accommodation daily life, as postprandial fullness, early satiation, epigastric pain, and epigastric • 15 healthy volunteers (9 female, 6 male) • No significant differences in VAS scores before and after meal burning, without any underlying organic disease, is one of the most common • Mean age: 28.3±5.8 years ingestion and no significant differences in preprandial intragastric functional gastrointestinal disorders (1). volumes were observed. Itopride, a prokinetic drug with dopamine D2-antagonistic and cholinesterase Gastric compliance and gastric sensitivity • Postprandial gastric volumes and gastric accommodation were inhibitor properties, is frequently used to treat functional dyspepsia. Its effects I50, I100, and D10 did not affect fasting or postprandial gastric significantly lower for I50 and for D10, compared to placebo. on gastric sensitivity and accommodation are unknown (2), compliance and gastric sensitivity to distention significantly The aim of this study is to evaluate the effect of Itopride, compared to compared to placebo. Domperidone, a dopamine D2 receptor antagonist, on the sensitivity to gastric * Placebo balloon
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Download Drug Labels List
    Syringe Labelling System Price Per Label Description/Drug Name Item No. Quanitiy Per Pack Pack Abciximab 99801 2 x 500 roll's £6.30 Abidec 100602 2 x 500 roll's £6.30 Acepromazine 99802 2 x 500 roll's £6.30 Acetazolamide 99803 2 x 500 roll's £6.30 Acetylcholine 99804 2 x 500 roll's £6.30 Acetylcysteine 99805 2 x 500 roll's £6.30 Acetylsalicylic Acid 99806 2 x 500 roll's £6.30 Aciclovir 99807 2 x 500 roll's £6.30 ACP/Buprenorphine 100208 2 x 500 roll's £6.30 Actrapid Insulin 99808 2 x 500 roll's £6.30 Adenosine 99809 2 x 500 roll's £6.30 Adrenaline (Top Half Black, Bottom Violet, Violet Text) 99810 2 x 500 roll's £6.30 Adrenaline/Epinephrine 99811 2 x 500 roll's £6.30 Albumin Solution 99812 2 x 500 roll's £6.30 Alchol 99813 2 x 500 roll's £6.30 Alemtuzmab 99814 2 x 500 roll's £6.30 ALERT 100243 2 x 500 roll's £6.30 Alfaxalone 99815 2 x 500 roll's £6.30 Alfentanil 99816 2 x 500 roll's £6.30 Alfentanil 99817 2 x 500 roll's £6.30 Alteplase 99818 2 x 500 roll's £6.30 Amikacin 99819 2 x 500 roll's £6.30 Aminophylline 99820 2 x 500 roll's £6.30 Amiodarone 100194 2 x 500 roll's £6.30 Amoxicillin 100195 2 x 500 roll's £6.30 Amphotericin 99821 2 x 500 roll's £6.30 Ampicillin 99822 2 x 500 roll's £6.30 Antibiotic 99823 2 x 500 roll's £6.30 Anticoagulant 99824 2 x 500 roll's £6.30 Antifungal 100228 2 x 500 roll's £6.30 Antiseptic 99825 2 x 500 roll's £6.30 Aprotinin 99826 2 x 500 roll's £6.30 Aqueous Iodine 99827 2 x 500 roll's £6.30 Arterial 100259 2 x 500 roll's £6.30 Arterial ( Line Label - White with Red Writing) 100176 2 x 500 roll's £6.30 Arterial
    [Show full text]
  • A Comparative Evaluation of Lafutidine and 2 Rabeprazole in The
    1 *Original research paper 2 A comparative evaluation of Lafutidine and 3 Rabeprazole in the treatment of gastritis and 4 peptic ulcer: A double-blind, randomized study 5 in Indian patients. 6 Dr. Sanjay Kumar 1, Dr. Bhupesh Dewan 2*, Deepashri Shah 2 7 8 1Global Liver and Gastroenterology Centre, Bhopal, India 2 9 Medical Department, Zuventus Healthcare Ltd., Mumbai, India 10 11 . 12 ABSTRACT 13 Aims: To assess the efficacy of lafutidine therapy versus rabeprazole in Indian patients with endoscopically and histologically proven gastritis and peptic ulcer. Study design: A double blind, double dummy, randomized, comparative study. Place and Duration of Study: Global Liver and Gastroenterology Centre, Bhopal, India, between March 2010 and October 2010. Methodology: A total of 100 patients were enrolled, including 50 with endoscopically and histologically proven gastritis and other 50 with peptic ulcer (over 5 mm in diameter). Each group was randomized to receive either lafutidine or rabeprazole tablet and their corresponding competitor placebo dummy tablet, for a period of 4 weeks. Gastritis/ulcer cure rates confirmed by endoscopic histology, symptom response and Helicobacter pylori (H. Pylori) eradication were compared among the two drugs Results: Complete cure of gastritis was observed in all the patients (100%) treated with lafutidine and 95.24% [20/21; 95% CI: 76.18 to 99.88%] patients treated with rabeprazole. Complete cure of ulcer was observed in 72.0% (18/25, 95% CI = 50.61 to 87.93%) and 79.16% (19/24, 95% CI = 57.85 to 92.87%) patients treated with lafutidine and rabeprazole respectively. There was no significant difference in gastritis/ulcer cure rate and symptom response rate between the two treatment groups at the end of the study.
    [Show full text]
  • 4 Supplementary File
    Supplemental Material for High-throughput screening discovers anti-fibrotic properties of Haloperidol by hindering myofibroblast activation Michael Rehman1, Simone Vodret1, Luca Braga2, Corrado Guarnaccia3, Fulvio Celsi4, Giulia Rossetti5, Valentina Martinelli2, Tiziana Battini1, Carlin Long2, Kristina Vukusic1, Tea Kocijan1, Chiara Collesi2,6, Nadja Ring1, Natasa Skoko3, Mauro Giacca2,6, Giannino Del Sal7,8, Marco Confalonieri6, Marcello Raspa9, Alessandro Marcello10, Michael P. Myers11, Sergio Crovella3, Paolo Carloni5, Serena Zacchigna1,6 1Cardiovascular Biology, 2Molecular Medicine, 3Biotechnology Development, 10Molecular Virology, and 11Protein Networks Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 34149, Trieste, Italy 4Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy 5Computational Biomedicine Section, Institute of Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany 6Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy 7National Laboratory CIB, Area Science Park Padriciano, Trieste, 34149, Italy 8Department of Life Sciences, University of Trieste, Trieste, 34127, Italy 9Consiglio Nazionale delle Ricerche (IBCN), CNR-Campus International Development (EMMA- INFRAFRONTIER-IMPC), Rome, Italy This PDF file includes: Supplementary Methods Supplementary References Supplementary Figures with legends 1 – 18 Supplementary Tables with legends 1 – 5 Supplementary Movie legends 1, 2 Supplementary Methods Cell culture Primary murine fibroblasts were isolated from skin, lung, kidney and hearts of adult CD1, C57BL/6 or aSMA-RFP/COLL-EGFP mice (1) by mechanical and enzymatic tissue digestion. Briefly, tissue was chopped in small chunks that were digested using a mixture of enzymes (Miltenyi Biotec, 130- 098-305) for 1 hour at 37°C with mechanical dissociation followed by filtration through a 70 µm cell strainer and centrifugation.
    [Show full text]
  • Drug Screen Req. 06.2016.Docx Rev 2 Date 06-16 Page 1 of 2
    TRUESDAIL LABORATORIES, INC. EXCELLENCE IN INDEPENDENT TESTING Established 1931 3337 MICHELSON DRIVE, SUITE CN 750 IRVINE, CALIFORNIA 92612 (714) 730-6239 FAX (714) 730-6462 www. truesdail.com DRUG SCREEN REQUEST FORM SAMPLE TYPE: Urine Blood Plasma Serum Collection Date: ______________ Doctor: ______________________________ Animal Name, HIP # or Other I.D.:______________________________________ Species: _________ Sex: ________ Owner’s name:_______________________ Pre-Purchase Screening (performed by LC/MS) LEVEL Ι: Includes only nonsteroidal anti-inflammatory drugs (phenylbutazone, $100.00 oxyphenbutazone, flunixin, naproxen, ketoprofen, firocoxib, diclofenac and meclofenamic acid). (Requires a minimum of 2 mL serum or plasma or 10mL of urine) LEVEL ΙΙ: Includes LEVEL Ι drugs plus testing for Domosedan (detomidine), $175.00 fluphenazine, acepromazine, promazine, chlorpromazine, triflupromazine, imipramine, propionylpromazine, clomipramine, and reserpine. (Requires a minimum of 4 mL of serum or plasma or 15mL of urine) LEVEL ΙΙΙ: Includes LEVEL Ι and ΙΙ drugs plus testing for butorphanol, triamcinolone $250.00 acetonide, betamethasone, dexamethasone, flumethasone, isoflupredone, predisone, methylprednisolone, prednisolone, albuterol, clenbuterol, terbutaline, and pirbuterol. (Requires a minimum of 5 mL of serum or plasma or 20mL of urine) LEVEL ΙV: TOBA Protocol Testing (urine and blood is required for this test) $300.00 (Requires a minimum of 6 mL of serum or plasma and 25mL of urine) *Rush testing is available for Level I, II or III
    [Show full text]
  • Histamine H2-Receptor Antagonists Improve Non-Steroidal Anti-Inflammatory Drug-Induced Intestinal Dysbiosis
    International Journal of Molecular Sciences Article Histamine H2-Receptor Antagonists Improve Non-Steroidal Anti-Inflammatory Drug-Induced Intestinal Dysbiosis Rei Kawashima, Shun Tamaki, Fumitaka Kawakami, Tatsunori Maekawa and Takafumi Ichikawa * Department of Regulation Biochemistry, Kitasato University Graduate School of Medical Sciences, Kanagawa 252-0374, Japan; [email protected] (R.K.); [email protected] (S.T.); [email protected] (F.K.); [email protected] (T.M.) * Correspondence: [email protected]; Tel.: +81-42-778-8863 Received: 8 October 2020; Accepted: 30 October 2020; Published: 31 October 2020 Abstract: Dysbiosis, an imbalance of intestinal flora, can cause serious conditions such as obesity, cancer, and psychoneurological disorders. One cause of dysbiosis is inflammation. Ulcerative enteritis is a side effect of non-steroidal anti-inflammatory drugs (NSAIDs). To counteract this side effect, we proposed the concurrent use of histamine H2 receptor antagonists (H2RA), and we examined the effect on the intestinal flora. We generated a murine model of NSAID-induced intestinal mucosal injury, and we administered oral H2RA to the mice. We collected stool samples, compared the composition of intestinal flora using terminal restriction fragment length polymorphism, and performed organic acid analysis using high-performance liquid chromatography. The intestinal flora analysis revealed that NSAID [indomethacin (IDM)] administration increased Erysipelotrichaceae and decreased Clostridiales but that both had improved with the concurrent administration of H2RA. Fecal levels of acetic, propionic, and n-butyric acids increased with IDM administration and decreased with the concurrent administration of H2RA. Although in NSAID-induced gastroenteritis the proportion of intestinal microorganisms changes, leading to the deterioration of the intestinal environment, concurrent administration of H2RA can normalize the intestinal flora.
    [Show full text]